<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-57168" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Iodine-131 Uptake Study</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yavuz</surname>
            <given-names>Sahzene</given-names>
          </name>
          <aff>Virginia Commonwealth University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Puckett</surname>
            <given-names>Yana</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sahzene Yavuz declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yana Puckett declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>10</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-57168.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>An iodine-131 (I-131) scan is a noninvasive radionuclide imaging procedure used to visualize the functionality of thyroid tissue, detect metastatic thyroid cancer, and assess the remaining thyroid tissue after thyroidectomy. The thyroid gland plays a vital role in producing essential thyroid hormones necessary for survival and regulating energy metabolism. The ingested iodine, critical for thyroid hormone production, is selectively absorbed by thyroid follicular cells and facilitated by sodium iodide symporters (NIS).<xref ref-type="bibr" rid="article-57168.r1">[1]</xref>&#x000a0;</p>
        <p>Thyroid-stimulating hormone (TSH) controls the function of the NIS, allowing the body to absorb the circulating iodine in the form of iodide salt. When iodide enters follicular cells, it undergoes oxidation by the thyroid peroxidase enzyme to convert iodide into iodine. Organification is the subsequent biochemical reaction that integrates iodine into thyroglobulin, thereby synthesizing the thyroid hormones thyroxine (T4) and triiodothyronine (T3).</p>
        <p>Iodine molecules can be labeled with radiotracers and utilized for both diagnostic and therapeutic applications in diverse thyroid conditions, including Graves disease, toxic multinodular goiter, and thyroid cancer. The 2 most frequently used radiotracers for thyroid tissue scans are I-123 and I-131.</p>
        <p>The primary differences between the 2&#x000a0;radiotracers&#x000a0;are:</p>
        <list list-type="bullet">
          <list-item>
            <p>I-123 has a half-life of approximately 13 hours, decays by gamma emission, and delivers superior image quality. I-123 is expensive and less readily available, and it is primarily used for imaging of the thyroid gland in cases of benign thyroid disease, such as thyroid nodules and multinodular goiter. Although I-123 can be used for imaging and monitoring thyroid cancer, its reduced sensitivity in detecting pulmonary metastases, cost considerations, and limited availability make I-131 the preferred choice.<xref ref-type="bibr" rid="article-57168.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>I-131 has a half-life of approximately 8.2 days, decays through beta emission, and is more cost-effective and widely accessible.<xref ref-type="bibr" rid="article-57168.r2">[2]</xref>&#x000a0;1-131 is primarily utilized for imaging in cases of thyroid cancer.</p>
          </list-item>
        </list>
        <p>I-131 is utilized to treat differentiated thyroid cancer after thyroidectomy, toxic adenoma, toxic multinodular goiter, and Graves disease. The ingestion of radioiodine induces thyroid cell death through the emission of beta particles. The use of I-131 in both the treatment and diagnosis of thyroid cancer exemplifies theranostics, which is a concept that integrates diagnostic imaging and therapeutic intervention for a particular condition by using the same radiolabeled molecule, either in a modified form or with varying radiolabeled agent doses.<xref ref-type="bibr" rid="article-57168.r2">[2]</xref><xref ref-type="bibr" rid="article-57168.r3">[3]</xref>&#x000a0;</p>
        <p>A whole-body pre-radioiodine assessment, post-radioiodine treatment evaluation, and ongoing surveillance for thyroid cancer are all valid applications for an I-131 scan. Pre-radioiodine treatment scans are conducted less frequently. After a thyroidectomy, most patients usually retain some remnant thyroid tissue in their bodies. They may then be given a therapeutic dose of I-131 and undergo a post-radioiodine scan.&#x000a0;Pretreatment I-131 scans should be considered when surgical procedures and neck ultrasonography fail to assess the extent of residual disease clearly. In addition, the scans may be warranted when residual disease may influence the decision regarding the dose or necessity of radioiodine treatment.</p>
      </sec>
      <sec id="article-57168.s2" sec-type="Procedures">
        <title>Procedures</title>
        <p>
<bold>Preparation</bold>
</p>
        <p>Pregnancy and breastfeeding are contraindications, as a developing fetus can start absorbing radioactive iodine at approximately 10 weeks of gestation. Patients are advised to follow a low-iodine diet for approximately 7 to 14 days before the procedure. This dietary regimen excludes iodized salt, dairy products, egg yolks, and seafood while emphasizing the consumption of fresh vegetables, fruits, meats, and noniodized or kosher salt. The dietary restrictions are intended to improve the efficacy of I-131 therapy and the accuracy of pre- and post-therapy scans using I-131. Nevertheless, a recent comparative study did not reveal any significant difference in the response to radioactive iodine therapy for Graves disease between patients who adhered to a low-iodine diet and those who did not.<xref ref-type="bibr" rid="article-57168.r2">[2]</xref></p>
        <p>Patients undergoing treatment with antithyroid medications for hyperthyroidism are advised to discontinue these medications for 5 to 7 days to enhance iodine uptake. However, in severe hyperthyroidism, where discontinuing the medications could be detrimental, the discontinuation period may be reduced to 3 days.</p>
        <p>Elevating TSH levels enhances iodine uptake and optimizes imaging. The optimal TSH level for the test or potential treatment is 30 mIU/L or higher.<xref ref-type="bibr" rid="article-57168.r2">[2]</xref>&#x000a0;</p>
        <p>There are 2 ways to achieve elevated TSH levels, as mentioned below.</p>
        <list list-type="order">
          <list-item>
            <p><bold>Withdrawal of thyroid hormone:</bold>&#x000a0;Thyroid hormone withdrawal is recommended for patients with advanced and high-risk thyroid cancer. Patients who have undergone total or near-total thyroidectomy should discontinue thyroid replacement therapy for a period of 4 to 6 weeks before the procedure to induce pituitary TSH secretion. This recommendation is relevant for patients receiving thyroid hormones either as replacement therapy or suppressive doses. Due to its shorter half-life, reducing the discontinuation period to 2 weeks when using triiodothyronine may be feasible.<xref ref-type="bibr" rid="article-57168.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Preparation with thyrotropin alfa:</bold>&#x000a0;Thyrotropin alfa, a recombinant TSH (rhTSH) molecule, increases TSH levels without discontinuing thyroid hormone replacement, thus preventing hypothyroidism symptoms.<xref ref-type="bibr" rid="article-57168.r2">[2]</xref> The dosing regimen involves 2 subcutaneous injections of 0.9 mg each, administered to patients 24 hours apart. The American Thyroid Association (ATA) approves this method for remnant ablation after total thyroidectomy in patients with differentiated thyroid cancer who do not exhibit distant metastasis.<xref ref-type="bibr" rid="article-57168.r2">[2]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Procedures</bold>
</p>
        <p>In a pre-ablation or surveillance I-131 scan, patients ingest a small dose of radioactive iodine in the form of capsules or liquid, and the scan is typically performed 24 to 72 hours later.&#x000a0;Patients undergo post-therapy I-131 scans 3 to 7 days after an I-131 ablation or adjuvant therapy dose.</p>
        <p>The imaging procedure for I-131 involves specific patient preparations and positioning to ensure accurate results, as mentioned below.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>The patient must fast or abstain from eating for at least 4 hours before and up to 1 hour after taking the iodine dose.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The patient must recline in a supine position on a movable examination table to conduct this procedure. Before each series of images, they are instructed to consume a substantial amount of water to eliminate any potential physiological activity in the pharynx or esophagus.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A high-energy collimator &#x003b3;-camera equipped with I-131 sodium iodide is used to capture both anterior and posterior planar images, as well as spot images of the nasopharynx, thyroid bed, or chest.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A medium-energy collimator can be chosen instead of a low-energy collimator while using I-123, as it can improve image quality. The scanning procedure is typically conducted at the 18- to 24-hour intervals.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A single-photon emission computed tomography (SPECT) scan can examine the area from the skull base to the diaphragm and focus on any specific concerns found during the whole-body I-131 scan. This enhances the ability to detect both regional and distant metastasis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Serum thyroglobulin and anti-thyroglobulin antibody assays are obtained simultaneously.<xref ref-type="bibr" rid="article-57168.r4">[4]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-57168.s3" sec-type="Indications">
        <title>Indications</title>
        <p>An I-131 scan serves as a valuable diagnostic tool for examining various thyroid disorders, with primary applications including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Distinguishing hyperthyroidism from other types of thyrotoxicosis, although I-123 is more frequently utilized.</p>
          </list-item>
          <list-item>
            <p>Visualizing ectopic thyroid tissue.</p>
          </list-item>
          <list-item>
            <p>Visualizing remnants of normal or cancerous thyroid tissue and detecting thyroid cancer recurrence or distant metastasis.</p>
          </list-item>
          <list-item>
            <p>Restaging thyroid cancer typically occurs 6 to 12 months after thyroidectomy and radioactive iodine ablation therapy.</p>
          </list-item>
          <list-item>
            <p>Assisting in the calculation of the appropriate I-131 therapy dosage.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Determining the safest dosage of I-131 therapy for vital organs, particularly in cases where patients have undergone multiple prior treatments. This process is known as dosimetry.</p>
          </list-item>
          <list-item>
            <p>Determining the functionality of thyroid nodules.</p>
          </list-item>
          <list-item>
            <p>Evaluating congenital thyroid abnormalities, with the preference for I-123 due to its lower radiation exposure.<xref ref-type="bibr" rid="article-57168.r5">[5]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-57168.s4" sec-type="Potential Diagnosis">
        <title>Potential Diagnosis</title>
        <p>The potential diagnoses associated with thyroid-related conditions are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Graves disease</p>
          </list-item>
          <list-item>
            <p>Thyrotoxicosis due to Hashimoto disease</p>
          </list-item>
          <list-item>
            <p>Thyroiditis</p>
          </list-item>
          <list-item>
            <p>Presence of remnant thyroid tissue in the thyroid bed after total thyroidectomy</p>
          </list-item>
          <list-item>
            <p>Recurrence of differentiated thyroid cancer</p>
          </list-item>
          <list-item>
            <p>Metastasis of differentiated thyroid cancer</p>
          </list-item>
          <list-item>
            <p>Toxic multinodular goiter</p>
          </list-item>
          <list-item>
            <p>Toxic adenoma</p>
          </list-item>
          <list-item>
            <p>Ectopic thyroid tissue</p>
          </list-item>
          <list-item>
            <p>Excess exogenous thyroid hormone replacement</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-57168.s5" sec-type="Normal and Critical Findings">
        <title>Normal and Critical Findings</title>
        <p>
<bold>Physiological Uptake</bold>
</p>
        <p>Thyroid tissue exhibits a significant affinity for iodine uptake. Extra-thyroidal tissues such as the stomach, salivary glands, breast (particularly during lactation), and the urinary tract also contain NIS, resulting in physiological iodine uptake.<xref ref-type="bibr" rid="article-57168.r6">[6]</xref> As radioiodine is metabolized in the liver and subsequently excreted through the urinary tract, it is common to observe visualization of the liver, gallbladder, kidneys, bladder, and ureters during imaging.&#x000a0;</p>
        <p>Infected and inflamed tissues, cystic lesions, and ectopic thyroid tissue can also take up and trap I-131. Ectopic thyroid tissue, visualized on an I-131 scan, results from embryological remnants or malformations during the development of the thyroid gland. Typical examples include a lingual or sublingual thyroid, a thyroglossal duct, or a mediastinal thyroid gland.<xref ref-type="bibr" rid="article-57168.r6">[6]</xref><xref ref-type="bibr" rid="article-57168.r7">[7]</xref><xref ref-type="bibr" rid="article-57168.r8">[8]</xref></p>
        <p>
<bold>Pathological Uptake</bold>
</p>
        <p>After a thyroidectomy, any radioiodine uptake that deviates from the anticipated physiological distribution observed on a post-therapy I-131 scan is indicative of either remnant thyroid tissue or metastatic disease. Conducting a whole-body scan after therapy&#x000a0;is crucial to influence the treatment plan based on the results.<xref ref-type="bibr" rid="article-57168.r9">[9]</xref></p>
        <p>Increased blood flow and the presence of&#x000a0;NIS in tumors enable iodine uptake in conditions such as breast cancer, gastric adenocarcinoma, or bronchial adenocarcinoma.<xref ref-type="bibr" rid="article-57168.r6">[6]</xref> External contamination by body fluids or, in rare cases, iodine ingestion can mimic metastatic involvement. Typically, this pattern is readily recognized by experienced healthcare professionals and is correlated clinically with the patient's medical history and laboratory results.<xref ref-type="bibr" rid="article-57168.r10">[10]</xref> These observations typically involve superficial areas, and acquiring lateral and oblique images helps to identify the lesion. Furthermore, using SPECT can provide valuable information regarding the anatomical location of the uptake for further assessment.</p>
        <p>Patients with hyperthyroidism with elevated or normal radioiodine uptake indicate Graves disease or thyrotoxicosis due to Hashimoto disease. Individuals exhibiting nearly absent radioiodine uptake may have thyroiditis, an excessive or intentional thyroid replacement, or ectopic hyperthyroidism, such as metastatic follicular thyroid cancer or struma ovarii.</p>
      </sec>
      <sec id="article-57168.s6" sec-type="Interfering Factors">
        <title>Interfering Factors</title>
        <p>Thyroid stunning refers to inhibiting the uptake or retention of I-131 after administering a diagnostic dose. Stunning is a transient phenomenon and occurs less frequently with I-123. Therefore, I-123 is the preferred radiotracer for imaging benign thyroid conditions. Stunning occurs due to the reduction in the number of functioning thyroid cells caused by radiation emitted during the test.<xref ref-type="bibr" rid="article-57168.r11">[11]</xref>&#x000a0;</p>
        <p>When a small dose of I-131 is administered before a larger treatment dose, it may lead to a phenomenon called "stunning" of thyroid cells, potentially diminishing the treatment's efficacy. Radioactive iodine therapy is approved and deemed safe for both adults and children.<xref ref-type="bibr" rid="article-57168.r12">[12]</xref></p>
        <p>Certain medications can disrupt iodine uptake in the thyroid. To prepare for scanning, the use of the following medications for the specified duration should be discontinued before the procedure:</p>
        <list list-type="bullet">
          <list-item>
            <p>Methimazole for 3 to 5 days</p>
          </list-item>
          <list-item>
            <p>Propylthiouracil for 3 to 5 days</p>
          </list-item>
          <list-item>
            <p>Bromides for 1 week</p>
          </list-item>
          <list-item>
            <p>Mercurials for 1 week</p>
          </list-item>
          <list-item>
            <p>Nitrates for 1 week</p>
          </list-item>
          <list-item>
            <p>Perchlorate for 1 week</p>
          </list-item>
          <list-item>
            <p>Salicylates, in large doses, for 1 week</p>
          </list-item>
          <list-item>
            <p>Sulfonamides for 1 week</p>
          </list-item>
          <list-item>
            <p>Thiocyanate for 1 week</p>
          </list-item>
          <list-item>
            <p>Iodine-containing cough medicines and vitamins for 2 weeks</p>
          </list-item>
          <list-item>
            <p>Iodine solution (Lugol) for 2 to 3 weeks</p>
          </list-item>
          <list-item>
            <p>Iodine-containing topical agents for 2 to 3 weeks</p>
          </list-item>
          <list-item>
            <p>Kelp for 2 to 3 weeks</p>
          </list-item>
          <list-item>
            <p>T3 for 2 to 3 weeks</p>
          </list-item>
          <list-item>
            <p>Levothyroxine (T4) for 4 to 6 weeks&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Thyroid extracts or desiccated thyroid extracts for 4 weeks</p>
          </list-item>
          <list-item>
            <p>Intravenous iodinated contrast materials for 4 to 6 weeks</p>
          </list-item>
          <list-item>
            <p>Oil-based iodinated contrast materials for 3 to 6 months</p>
          </list-item>
          <list-item>
            <p>Amiodarone for 3 to 6 months</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-57168.s7" sec-type="Complications">
        <title>Complications</title>
        <p>Numerous complications associated with an I-131 scan stem from either the preparatory steps preceding the scan or prior treatment with I-131 before post-ablative scans. Some complications include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypothyroidism-associated symptoms include fatigue, depression, weight gain, constipation, muscle aches, and decreased concentration.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Rapid growth of persistent or metastatic thyroid cancer with elevated TSH levels, potentially&#x000a0;leading to airway obstruction or bone pain after rhTSH administration, in rare cases.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Secondary malignancies&#x000a0;due to&#x000a0;I-131 treatment.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Transient oligospermia and decreases in ovarian function as a result of I-131 treatment.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Nausea, salivary gland inflammation, or dry mouth due to the therapy with I-131.<xref ref-type="bibr" rid="article-57168.r13">[13]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Bone marrow suppression with higher accumulated doses of iodine.<xref ref-type="bibr" rid="article-57168.r14">[14]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Mild anemia, low white blood count, or thrombocytopenia that is not typically clinically significant.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Mild, transient hyponatremia and hypokalemia due to the induced hypothyroid state.<xref ref-type="bibr" rid="article-57168.r15">[15]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Increased risk of thyroid cancer and increased mortality from breast cancer after iodine therapy for Graves disease.<xref ref-type="bibr" rid="article-57168.r16">[16]</xref><xref ref-type="bibr" rid="article-57168.r17">[17]</xref><xref ref-type="bibr" rid="article-57168.r18">[18]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Moderate-to-severe thyroid eye disease that can worsen with I-131 treatment and is a relative contraindication.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Stunning of the normal thyroid tissue that can diminish the effectiveness of therapeutic I-131 doses.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-57168.s8" sec-type="Patient Safety and Education">
        <title>Patient Safety and Education</title>
        <p>In the interest of patient safety and education, adhering to specific guidelines following I-131 ablation or adjuvant therapy is crucial, some of which are mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients should practice self-isolation following I-131 ablation or adjuvant therapy, considering their dose and patient-specific characteristics, according to nuclear medicine recommendations.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients intending to travel by air should be aware that they may trigger radiation detectors for approximately 2 to 3 months and should carry an official letter confirming this.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients are advised to refrain from becoming pregnant for 6 months following radioactive iodine treatment.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients should&#x000a0;cease breastfeeding for at least 6 weeks before undergoing the test or treatment to prevent increased uptake and radiation absorption in breast tissue.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients are recommended to&#x000a0;discontinue breastfeeding following&#x000a0;I-131 administration. Subsequent pregnancies may allow for the resumption of breastfeeding. However, after I-123 administration, breastfeeding can safely resume after a waiting period of 72 hours.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-57168.s9" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>An I-131 scan is an important imaging tool for diagnosing and treating thyroid disorders. Performing pre- and post-therapy scans in patients with differentiated thyroid cancer enables disease surveillance and assists clinicians in determining the most suitable treatment approach. Furthermore, it is essential to identify potentially false-positive and false-negative imaging findings during interpretation and correlate them with the patient's characteristics.</p>
      </sec>
      <sec id="article-57168.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=57168&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=57168">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/57168/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=57168">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-57168.s11">
        <title>References</title>
        <ref id="article-57168.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Portulano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Paroder-Belenitsky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carrasco</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>The Na+/I- symporter (NIS): mechanism and medical impact.</article-title>
            <source>Endocr Rev</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>106</fpage>
            <page-range>106-49</page-range>
            <pub-id pub-id-type="pmid">24311738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57168.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choudhury</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Differentiated thyroid cancer theranostics: radioiodine and beyond.</article-title>
            <source>Br J Radiol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>91</volume>
            <issue>1091</issue>
            <fpage>20180136</fpage>
            <pub-id pub-id-type="pmid">30260232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57168.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ehrhardt</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>G&#x000fc;le&#x000e7;</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A Review of the History of Radioactive Iodine Theranostics: The Origin of Nuclear Ontology.</article-title>
            <source>Mol Imaging Radionucl Ther</source>
            <year>2020</year>
            <month>Oct</month>
            <day>19</day>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>88</fpage>
            <page-range>88-97</page-range>
            <pub-id pub-id-type="pmid">33094571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57168.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>SPECT/CT in the Treatment of Differentiated Thyroid Cancer.</article-title>
            <source>Nucl Med Mol Imaging</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>297</fpage>
            <page-range>297-303</page-range>
            <pub-id pub-id-type="pmid">29242723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57168.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Intenzo</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Dam</surname>
                <given-names>HQ</given-names>
              </name>
              <name>
                <surname>Manzone</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Imaging of the thyroid in benign and malignant disease.</article-title>
            <source>Semin Nucl Med</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-61</page-range>
            <pub-id pub-id-type="pmid">22117813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57168.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oral</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yaz&#x00131;c&#x00131;</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Eraslan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Burak</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Unexpected False-positive I-131 Uptake in Patients with Differentiated Thyroid Carcinoma.</article-title>
            <source>Mol Imaging Radionucl Ther</source>
            <year>2018</year>
            <month>Oct</month>
            <day>09</day>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>99</fpage>
            <page-range>99-106</page-range>
            <pub-id pub-id-type="pmid">30317832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57168.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glazer</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Savas</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Avram</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>SPECT/CT evaluation of unusual physiologic radioiodine biodistributions: pearls and pitfalls in image interpretation.</article-title>
            <source>Radiographics</source>
            <year>2013</year>
            <season>Mar-Apr</season>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>397</fpage>
            <page-range>397-418</page-range>
            <pub-id pub-id-type="pmid">23479704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57168.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hannoush</surname>
                <given-names>ZC</given-names>
              </name>
              <name>
                <surname>Palacios</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Kuker</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Casula</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>False Positive Findings on I-131 WBS and SPECT/CT in Patients with History of Thyroid Cancer: Case Series.</article-title>
            <source>Case Rep Endocrinol</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>8568347</fpage>
            <pub-id pub-id-type="pmid">28246564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57168.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Llamas-Olier</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Cu&#x000e9;llar</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Buitrago</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Intermediate-Risk Papillary Thyroid Cancer: Risk Factors for Early Recurrence in Patients with Excellent Response to Initial Therapy.</article-title>
            <source>Thyroid</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>10</issue>
            <fpage>1311</fpage>
            <page-range>1311-1317</page-range>
            <pub-id pub-id-type="pmid">30105948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57168.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozcan Kara</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gunay</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Erdogan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Radioiodine Contamination Artifacts and Unusual Patterns of Accumulation in Whole-body I-131 Imaging: A Case Series.</article-title>
            <source>Int J Endocrinol Metab</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>e9329</fpage>
            <pub-id pub-id-type="pmid">24696698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57168.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Happel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kranert</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Gr&#x000f6;ner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bockisch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sabet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vardarli</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>G&#x000f6;rges</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;nwald</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Correction for hyperfunctioning radiation-induced stunning (CHRIS) in benign thyroid diseases.</article-title>
            <source>Endocrine</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>69</volume>
            <issue>2</issue>
            <fpage>466</fpage>
            <page-range>466-473</page-range>
            <pub-id pub-id-type="pmid">32173798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57168.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lutterman</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Zwaveling-Soonawala</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Verberne</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Verburg</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>van Trotsenburg</surname>
                <given-names>ASP</given-names>
              </name>
              <name>
                <surname>Mooij</surname>
                <given-names>CF</given-names>
              </name>
            </person-group>
            <article-title>The Efficacy and Short- and Long-Term Side Effects of Radioactive Iodine Treatment in Pediatric Graves' Disease: A Systematic Review.</article-title>
            <source>Eur Thyroid J</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>10</volume>
            <issue>5</issue>
            <fpage>353</fpage>
            <page-range>353-363</page-range>
            <pub-id pub-id-type="pmid">34540705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57168.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000e1;nchez Barrueco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez Gal&#x000e1;n</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Alcal&#x000e1; Rueda</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Santill&#x000e1;n Coello</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Barrio Dorado</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Villacampa Aub&#x000e1;</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Escanciano Escanciano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Llanos Jim&#x000e9;nez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mahillo Fern&#x000e1;ndez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cenjor Espa&#x000f1;ol</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Incidence and risk factors for radioactive iodine-induced sialadenitis.</article-title>
            <source>Acta Otolaryngol</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>140</volume>
            <issue>11</issue>
            <fpage>959</fpage>
            <page-range>959-962</page-range>
            <pub-id pub-id-type="pmid">32815758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57168.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reinecke</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ahlers</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Burchert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eilsberger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Flux</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Marlowe</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Reiners</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rohde</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>van Santen</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Luster</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidence.</article-title>
            <source>Eur J Nucl Med Mol Imaging</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>49</volume>
            <issue>9</issue>
            <fpage>3247</fpage>
            <page-range>3247-3256</page-range>
            <pub-id pub-id-type="pmid">35320386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57168.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takata</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Miyagawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kawaguchi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kouchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tsuruoka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Uwatsu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kido</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Effect of preparation method for radioactive iodine therapy on serum electrolytes.</article-title>
            <source>Jpn J Radiol</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>41</volume>
            <issue>11</issue>
            <fpage>1247</fpage>
            <page-range>1247-1254</page-range>
            <pub-id pub-id-type="pmid">37184818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57168.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shim</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Kitahara</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Cha</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Bang</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Cancer Risk After Radioactive Iodine Treatment for Hyperthyroidism: A Systematic Review and Meta-analysis.</article-title>
            <source>JAMA Netw Open</source>
            <year>2021</year>
            <month>Sep</month>
            <day>01</day>
            <volume>4</volume>
            <issue>9</issue>
            <fpage>e2125072</fpage>
            <pub-id pub-id-type="pmid">34533571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57168.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Evron</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Esfandiari</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Papaleontiou</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cancer incidence and mortality following treatment of hyperthyroidism with radioactive iodine.</article-title>
            <source>Curr Opin Endocrinol Diabetes Obes</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>323</fpage>
            <page-range>323-328</page-range>
            <pub-id pub-id-type="pmid">32773569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57168.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kitahara</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Berrington de Gonzalez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bouville</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brill</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Doody</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Melo</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Sosa</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Tulchinsky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Villoing</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Preston</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Association of Radioactive Iodine Treatment With Cancer Mortality in Patients With Hyperthyroidism.</article-title>
            <source>JAMA Intern Med</source>
            <year>2019</year>
            <month>Aug</month>
            <day>01</day>
            <volume>179</volume>
            <issue>8</issue>
            <fpage>1034</fpage>
            <page-range>1034-1042</page-range>
            <pub-id pub-id-type="pmid">31260066</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
